SAN DIEGO, CA, Aug. 15, 2023 /PRNewswire/ — Inmagene Biopharmaceuticals (“Inmagene”), a clinical stage biotechnology company developing innovative and differentiated therapies for immunological […]
San Diego, Shanghai, Sydney April 28th , 2023 – Inmagene Biopharmaceuticals (“Inmagene”) today announced positive topline results from a Phase
At 12 weeks, participants achieved high orders of HiSCR responses (HiSCR75 and above), including 33% achieving HiSCR100. Safety results were
San Diego, Shanghai, and Sydney, February 6, 2023 – Inmagene Biopharmaceuticals (“Inmagene”) announced that the U.S. Food and Drug Administration
• Izokibep achieves higher orders of Hidradenitis Suppurativa Clinical Responses (HiSCR) in open label part of a Phase 2b/3 trial.
San Diego, Shanghai and Hong Kong — Tuesday, August 9, 2022: Inmagene Biopharmaceuticals (“Inmagene“) and HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM;
San Diego, Shanghai, Hong Kong and Sydney — Wednesday, July 6, 2022: Inmagene Biopharmaceuticals (“Inmagene“) and HUTCHMED (China) Limited (“HUTCHMED”)
San Diego, Shanghai, May 16, 2022 – Inmagene Biopharmaceuticals (“Inmagene”) announces that today the U.S. Food and Drug Administration (FDA)
San Diego, Shanghai and Sydney, May 7th, 2022 – Inmagene Biopharmaceuticals (“Inmagene”) announces that the U.S. Food and Drug Administration
SHANGHAI and SAN DIEGO and HANGZHOU, China, Nov. 17, 2021 — Inmagene Biopharmaceuticals (“Inmagene” or the “Company”) announced that it has filed two international patent applications for
